Cargando…
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States
BACKGROUND: Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation. A subsequent study reported XMRV antigens in malignant prostatic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077333/ https://www.ncbi.nlm.nih.gov/pubmed/21447170 http://dx.doi.org/10.1186/1742-4690-8-23 |
_version_ | 1782201867170742272 |
---|---|
author | Sakuma, Toshie Hué, Stéphane Squillace, Karen A Tonne, Jason M Blackburn, Patrick R Ohmine, Seiga Thatava, Tayaramma Towers, Greg J Ikeda, Yasuhiro |
author_facet | Sakuma, Toshie Hué, Stéphane Squillace, Karen A Tonne, Jason M Blackburn, Patrick R Ohmine, Seiga Thatava, Tayaramma Towers, Greg J Ikeda, Yasuhiro |
author_sort | Sakuma, Toshie |
collection | PubMed |
description | BACKGROUND: Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation. A subsequent study reported XMRV antigens in malignant prostatic epithelium and association of XMRV infection with PCa, especially higher-grade tumors, independently of the RNASEL polymorphism. Further studies showed high prevalence of XMRV or related MLV sequences in chronic fatigue syndrome patients (CFS), while others found no, or low, prevalence of XMRV in a variety of diseases including PCa or CFS. Thus, the etiological link between XMRV and human disease remains elusive. To address the association between XMRV infection and PCa, we have tested prostate tissues and human sera for the presence of viral DNA, viral antigens and anti-XMRV antibodies. RESULTS: Real-time PCR analysis of 110 PCa (Gleason scores >4) and 40 benign and normal prostate tissues identified six positive samples (5 PCa and 1 non-PCa). No statistical link was observed between the presence of proviral DNA and PCa, PCa grades, and the RNASEL R462Q mutation. The amplified viral sequences were distantly related to XMRV, but nearly identical to endogenous MLV sequences in mice. The PCR positive samples were also positive for mouse mitochondrial DNA by nested PCR, suggesting contamination of the samples with mouse DNA. Immuno-histochemistry (IHC) with an anti-XMRV antibody, but not an anti-MLV antibody that recognizes XMRV, sporadically identified antigen-positive cells in prostatic epithelium, irrespectively of the status of viral DNA detection. No serum (159 PCa and 201 age-matched controls) showed strong neutralization of XMRV infection at 1:10 dilution. CONCLUSION: The lack of XMRV sequences or strong anti-XMRV neutralizing antibodies indicates no or very low prevalence of XMRV in our cohorts. We conclude that real-time PCR- and IHC-positive samples were due to laboratory contamination and non-specific immune reactions, respectively. |
format | Text |
id | pubmed-3077333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30773332011-04-15 No evidence of XMRV in prostate cancer cohorts in the Midwestern United States Sakuma, Toshie Hué, Stéphane Squillace, Karen A Tonne, Jason M Blackburn, Patrick R Ohmine, Seiga Thatava, Tayaramma Towers, Greg J Ikeda, Yasuhiro Retrovirology Research BACKGROUND: Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation. A subsequent study reported XMRV antigens in malignant prostatic epithelium and association of XMRV infection with PCa, especially higher-grade tumors, independently of the RNASEL polymorphism. Further studies showed high prevalence of XMRV or related MLV sequences in chronic fatigue syndrome patients (CFS), while others found no, or low, prevalence of XMRV in a variety of diseases including PCa or CFS. Thus, the etiological link between XMRV and human disease remains elusive. To address the association between XMRV infection and PCa, we have tested prostate tissues and human sera for the presence of viral DNA, viral antigens and anti-XMRV antibodies. RESULTS: Real-time PCR analysis of 110 PCa (Gleason scores >4) and 40 benign and normal prostate tissues identified six positive samples (5 PCa and 1 non-PCa). No statistical link was observed between the presence of proviral DNA and PCa, PCa grades, and the RNASEL R462Q mutation. The amplified viral sequences were distantly related to XMRV, but nearly identical to endogenous MLV sequences in mice. The PCR positive samples were also positive for mouse mitochondrial DNA by nested PCR, suggesting contamination of the samples with mouse DNA. Immuno-histochemistry (IHC) with an anti-XMRV antibody, but not an anti-MLV antibody that recognizes XMRV, sporadically identified antigen-positive cells in prostatic epithelium, irrespectively of the status of viral DNA detection. No serum (159 PCa and 201 age-matched controls) showed strong neutralization of XMRV infection at 1:10 dilution. CONCLUSION: The lack of XMRV sequences or strong anti-XMRV neutralizing antibodies indicates no or very low prevalence of XMRV in our cohorts. We conclude that real-time PCR- and IHC-positive samples were due to laboratory contamination and non-specific immune reactions, respectively. BioMed Central 2011-03-29 /pmc/articles/PMC3077333/ /pubmed/21447170 http://dx.doi.org/10.1186/1742-4690-8-23 Text en Copyright ©2011 Sakuma et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sakuma, Toshie Hué, Stéphane Squillace, Karen A Tonne, Jason M Blackburn, Patrick R Ohmine, Seiga Thatava, Tayaramma Towers, Greg J Ikeda, Yasuhiro No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title | No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title_full | No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title_fullStr | No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title_full_unstemmed | No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title_short | No evidence of XMRV in prostate cancer cohorts in the Midwestern United States |
title_sort | no evidence of xmrv in prostate cancer cohorts in the midwestern united states |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077333/ https://www.ncbi.nlm.nih.gov/pubmed/21447170 http://dx.doi.org/10.1186/1742-4690-8-23 |
work_keys_str_mv | AT sakumatoshie noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT huestephane noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT squillacekarena noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT tonnejasonm noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT blackburnpatrickr noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT ohmineseiga noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT thatavatayaramma noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT towersgregj noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates AT ikedayasuhiro noevidenceofxmrvinprostatecancercohortsinthemidwesternunitedstates |